December 26, 2016
MSD said on December 22 that it has submitted an application seeking approval of its anti-PD-1 antibody Keytruda (pembrolizumab) for the treatment of Hodgkin’s lymphoma, which will be the drug’s third indication in Japan if approved. The application was filed...read more